EXCLUSIVE: Virax Biolabs Introduces Human Papillomavirus Test Kit In European Union

Virax Biolabs Group Ltd VRAX has announced the distribution of HPV test kits with shipments anticipated in Q1 of 2023 to the European Union. 

What Happened: The test kit covers 18 different genotypes of HPV, including type 53, which is a higher risk and becoming increasingly prevalent.

Virax's Chairman of the Board and Chief Executive Officer, James Foster, commented, "these tests will cover more genotypes, have shorter processing times, and lower costs than the currently available HPV tests in Europe. As we are able to supply around 200,000 of these tests per week, we have a significant opportunity to capture some market share."

Related Content: EXCLUSIVE: Virax Biolabs Launches RSV/Flu/COVID-19 Combo Rapid Test Kit In Europe.

Why It Matters: HPV is one of the most prevalent sexually transmitted infections in the developed world. HPV is also the primary cause of cervical cancer in women, with around 33,000 cases and 15,000 deaths annually in the EU, according to the European Centre for Disease Prevention and Control. 

Globally, HPV is estimated to cause over 600,000 cases of cervical cancer annually by the World Health Organization.

Price Action: VRAX shares are up 1.52% at $0.82 during the premarket session on the last check Wednesday.

Market News and Data brought to you by Benzinga APIs
Posted In: NewsPenny StocksHealth CareMarket-Moving ExclusivesExclusivesGeneral
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!